Form 8-K

8-K — MIRA PHARMACEUTICALS, INC.

Accession: 0001493152-26-027751

Filed: 2026-06-08

Period: 2026-06-02

CIK: 0001904286

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-10.1 (ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001904286

2026-06-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): June 2, 2026

MIRA

PHARMACEUTICALS, INC.

(Exact

Name of Registrant as Specified in its Charter)

Florida

001-41765

85-3354547

(State

or Other Jurisdiction

(Commission

(IRS

Employer

Incorporation)

File

Number)

Identification

No.)

1200

Brickell Avenue, Suite 1950 #1183

Miami,

Florida 33131

(Address

of Principal Executive Offices)

Registrant’s

telephone number, including area code: (786) 432-9792

Not

Applicable

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, $0.0001 par value per share

MIRA

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02

Departure

of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment

of Andriy Mushak as the Fractional Chief Financial Officer

Effective

June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”).

Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s

operations, policies, or practices. On June 2, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s

fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).

Mr.

Mushak, CPA, 43, is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience

in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting

Group, LLC (“LMAM”), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in

SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements,

financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries,

including technology, life sciences, media, medical supplies, finance, and manufacturing. Prior to co-founding LMAM in 2025, Mr. Mushak

served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial

statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master

of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak

is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.

Mr.

Mushak has been, and will remain, employed by LMAM and will be providing his services pursuant to the Consulting Agreement between the

Company and LMAM. The material terms of the engagement are that the Company will pay Mr. Mushak $6,000 per month for the services rendered

by Mr. Mushak.

There

are no family relationships, as defined in Item 401 of Regulation S-K, between Mr. Mushak and any of the Company’s executive officers

or directors or persons nominated or chosen to become a director or executive officer.

Mr.

Mushak has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation

S-K.

Item 9.01

Financial Statements and Exhibits

(d)

Exhibits

10.1

Consulting Agreement between MIRA Pharmaceuticals, Inc. and LMAM Consulting Group, LLC

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

MIRA

PHARMACEUTICALS, INC.

Dated:

June 8, 2026

By:

/s/

Erez Aminov

Name:

Erez

Aminov

Title:

Chief

Executive Officer

EX-10.1

Filename: ex10-1.htm · Sequence: 2

Exhibit

10.1

Consulting

Agreement

This

Consulting Agreement (this “Agreement”) is entered into as of June 6, 2026 (“Effective Date”) by and between

MIRA Pharmaceuticals, Inc. (“Company”), and Andriy Mushak (“Consultant”). Company and Consultant may be referred

to collectively as the “Parties” or individually as a “Party.”

Recitals

WHEREAS,

Consultant possesses expertise and experience in providing senior financial leadership, SEC reporting oversight, audit readiness, internal

controls, capital-markets support, budgeting, treasury oversight, and related strategic finance services; and

WHEREAS,

Company desires to engage Consultant to provide the services described in Section 1 below solely in Consultant’s capacity as a

fractional chief financial officer and not for any other services unless expressly added by a written amendment signed by both Parties;

and

WHEREAS,

the Parties desire to set forth the terms and conditions governing that engagement.

NOW,

THEREFORE, in consideration of the mutual covenants and promises set forth below, the Parties agree as follows:

Service Deliverables

MIRA

Pharmaceuticals, Inc. requires senior financial leadership to support its regulatory, capital-markets, and strategic-growth objectives.

In the capacity of Fractional Chief Financial Officer, Consultant will provide oversight of financial reporting, SEC compliance, audit

readiness, internal controls, capital-raising support, financial modeling, governance preparation, and board-level financial reporting,

as outlined below. The role is intended to establish and maintain rigorous financial discipline, support timely and accurate financial

reporting, strengthen Company’s capital-markets readiness, and provide strategic financial information to management and the Board.

Notwithstanding Consultant’s role as Fractional Chief Financial Officer, this Agreement does not create an employment relationship,

and Consultant shall at all times remain an independent contractor.

Consultant

will operate as an independent contractor in a flexible, outcome-driven capacity and will allocate sufficient time and professional attention

to fulfill the responsibilities and deliverables set forth herein. Services include (but are not limited to):

● Oversight

of the preparation, review, and coordination of SEC filings, including Forms 10-K, 10-Q,

and 8-K, together with coordination of annual audit and quarterly review processes.

● Leadership

over financial reporting processes, GAAP-compliant financial statements, monthly and quarterly

close support, and development and monitoring of internal controls over financial reporting.

● Audit

readiness support, including coordination with external auditors, completion of audit request

lists, remediation planning, and documentation support for accounting policies and procedures.

● Financial

modeling, budgeting, forecasting, liquidity planning, treasury oversight, banking relationship

support, and preparation of management and Board reporting packages.

● Capital-markets

and investor-reporting support, including financial materials, due diligence support, and

strategic finance analyses, as requested by Company.

For

the avoidance of doubt, this Agreement covers only the fractional CFO services expressly described in this Section 1. No other consulting,

operational, business development, legal, human resources, or unrelated services are included unless separately documented in a written

amendment signed by both Parties.

Compensation

The

Consultant shall receive cash compensation for services performed as Fractional Chief Financial Officer in the amount of $6,000 per month

(the “Compensation”). Payment shall be made within 5 days following receipt of an invoice or in accordance with the Company’s

standard accounts-payable cycle, as applicable.

Taxes

Consultant

acknowledges and agrees that all compensation provided under this Agreement constitutes non-employee compensation. Consultant shall be

solely responsible for all federal, state, and local taxes arising from compensation provided under this Agreement, including income

taxes and self-employment taxes. Company shall not withhold or remit taxes on Consultant’s behalf.

Expenses

Consultant

shall be responsible for payment of all expenses and costs incurred in connection with performing the Services, except for reasonable

third-party costs, such as authorized travel expenses, that are approved in writing by Company in advance. Any expenses incurred without

prior written approval shall not be reimbursed. If Consultant incurs expenses in connection with work for multiple clients, such expenses

shall be reasonably allocated so that Company pays only its proportionate share.

Use of Company Systems

Consultant

shall conduct Company business using Company-designated systems, software platforms, and communication channels, including Company-issued

email accounts and designated document repositories, except where expressly authorized in writing by Company. Consultant shall not exclusively

create, develop, maintain, or store Company materials, Work Product, data, models, or operational files within Consultant-owned or third-party

systems not accessible to Company. Any Company-related materials temporarily created or maintained within non-Company systems must be

contemporaneously uploaded to Company’s designated environment and shall not be retained solely within Consultant-controlled platforms.

Term and Termination

The

term of this Agreement shall commence on the Effective Date and continue for one (1) year, renewable and/or amendable by mutual written

agreement signed by both Parties, unless terminated earlier as provided herein (the “Term”). Either Party may terminate this

Agreement, with or without cause, by providing fourteen (14) days’ written notice (the “Notice Period”).

Company terminates this Agreement, Consultant shall be paid for the full Notice Period, whether required to continue providing Services

or released immediately. If Consultant terminates this Agreement, Company may, at its sole discretion, either request Consultant to continue

providing Services during the Notice Period with compensation for that period, or terminate the Agreement immediately, in which case

compensation shall be limited to Services actually rendered through the effective termination date.

Independent Contractor Relationship

Consultant

is an independent contractor, and all Services that Consultant performs for the benefit of Company shall be in Consultant’s capacity

as an independent contractor. Nothing in this Agreement shall be construed to create an agency, joint venture, partnership, or employment

relationship between Consultant and Company. Consultant shall have no authority to bind or obligate Company in any manner unless expressly

authorized in writing. Consultant acknowledges and agrees that Consultant is not eligible for, and shall not participate in, any Company

employee benefits, including without limitation health insurance, retirement benefits, workers’ compensation, unemployment compensation,

or paid time off.

Warranties and Representations

Consultant

represents and warrants that (a) Consultant is under no contractual or other restriction preventing Consultant from entering into and

performing under this Agreement; (b) Consultant shall comply with all applicable federal, state, and local laws, including without limitation

applicable securities laws, in connection with Consultant’s performance of the Services; and (c) Consultant has the experience

and qualifications reasonably necessary to perform the Services in a professional manner consistent with industry standards for a fractional

chief financial officer.

Conflict of Interest and Information Barriers

Consultant

may engage in other business activities and is not required to devote full time to Company, provided that such activities do not create

an actual conflict of interest with the Services or misuse Company Confidential Information. Consultant shall promptly disclose any actual

conflict of interest that arises during the Term and shall work in good faith with Company to address it.

Without

limiting the foregoing, the Parties acknowledge that Consultant may provide services to other clients, including clients operating in

the pharmaceutical, biotechnology, life sciences, or public-company sectors. Consultant shall maintain reasonable and appropriate information

barriers designed to prevent the disclosure, transfer, or misuse of any non-public, proprietary, or confidential information obtained

from Company in connection with services provided to any other client, and vice versa. Such information barriers shall include, as reasonably

applicable, separate electronic and physical file maintenance, separate workspaces and document repositories, access restrictions and

password protections, use of distinct client-designated communication channels, careful segregation of draft materials and work product,

and internal practices intended to avoid cross-use of confidential or proprietary information between clients.

Consultant

shall not use Company Confidential Information for the benefit of any other client or third party and shall not incorporate any other

client’s confidential or proprietary information into Company deliverables. Nothing in this Section shall prohibit Consultant from

using general knowledge, skills, experience, know-how, or publicly available information retained in unaided memory, provided that Consultant

does not disclose or use Company Confidential Information in violation of this Agreement.

10.

Management Responsibility and Reliance

Consultant’s

services are advisory and support services in nature. Company’s management, officers, and Board retain sole responsibility for

Company’s business, operations, books and records, disclosures, internal accounting decisions, internal control environment, final

accounting conclusions, public filings, certifications, and approval of all financial statements and SEC filings. Company acknowledges

that Consultant may rely in good faith on information, data, records, schedules, representations, access, and other materials provided

by Company personnel, Company management, the Board, external auditors, legal counsel, valuation firms, and other advisors engaged by

Company, unless Consultant has actual knowledge that such information is materially inaccurate or incomplete.

Consultant

shall not be responsible for independent verification of information furnished by Company or third parties absent a separate written

engagement expressly requiring such verification. Company remains responsible for implementing and maintaining internal controls, safeguarding

assets, and making all management decisions. Consultant’s advice, analyses, models, and work product are prepared for Company’s

internal use in connection with the Services and do not constitute legal opinions, investment banking advice, tax advice, valuation opinions,

or audit opinions unless separately agreed in writing. Reliance by Company on Consultant’s work product shall be subject to Company’s

review and approval, and Consultant shall not be liable for claims arising from inaccurate, incomplete, or untimely information supplied

by Company or its other advisors, except to the extent resulting from Consultant’s gross negligence, willful misconduct, or fraud.

11.

Company Property and Work Product

For

purposes of this Agreement, “Company Property” includes all property, materials, files, documents, data, communications,

equipment, systems, accounts, and other assets belonging to Company or any of its subsidiaries or affiliates, whether tangible or intangible,

whether created, accessed, or used by Consultant in the course of performing services. “Work Product” means all work product,

deliverables, documents, analyses, models, spreadsheets, presentations, financial statements, reports, correspondence, notes, data, information,

discoveries, developments, improvements, research, concepts, strategies, designs, writings, materials, or other items of any kind that

are conceived, created, drafted, prepared, modified, enhanced, or delivered by Consultant, alone or with others, in connection with the

Services performed under this Agreement.

All

Work Product shall be deemed the sole and exclusive property of Company from the moment of creation and shall constitute Company Property

for all purposes under this Agreement. Consultant hereby irrevocably assigns to Company all right, title, and interest in and to the

Work Product, including all intellectual property rights therein, without additional consideration beyond the compensation described

in this Agreement. Upon termination of the Agreement or upon request by Company at any time, Consultant shall promptly return or deliver

all Company Property and Work Product in Consultant’s possession, custody, or control, and shall permanently delete all copies

stored on any personal devices, drives, cloud accounts, or systems not owned by Company, subject to routine automated backup exceptions

that are not readily accessible in the ordinary course and remain subject to confidentiality obligations.

12.

Work Made for Hire

All

Work Product created by Consultant in connection with the Services shall be deemed a “work made for hire” to the fullest

extent permitted by law. To the extent any Work Product is not deemed a work made for hire, Consultant hereby irrevocably assigns to

Company all rights, title, and interest in and to such Work Product, including all intellectual property rights.

13.

Cybersecurity and Data Protection Requirements

Consultant

agrees to comply with all reasonable Company cybersecurity requirements, including without limitation use of multi-factor authentication

where required, appropriate password hygiene, secure storage and transmission of Company materials, no unauthorized forwarding of Company

documents to personal email accounts, and immediate discontinuation of system access upon termination of this Agreement. Consultant represents

that any remote work environment used to perform the Services will remain reasonably secure, private, and free from access by unauthorized

persons.

14.

Confidentiality

Consultant

agrees to hold in strict confidence all Confidential Information received in connection with the performance of Services. “Confidential

Information” means any non-public information disclosed by Company, whether oral, written, or electronic, including but not limited

to business plans, financial data, transaction information, financing plans, strategic initiatives, trade secrets, customer or vendor

information, scientific or product-development information, and non-public information regarding Company’s investors, shareholders,

employees, or Board. Consultant shall use such information solely for the purpose of providing Services to Company and shall not disclose

it to any third party without Company’s prior written consent, except as required by law. These obligations shall survive termination

of this Agreement.

15.

Insider Trading Policy

Consultant

acknowledges that, in the course of performing services under this Agreement, Consultant may become aware of material non-public information

concerning Company. Consultant agrees to comply with all applicable securities laws and with Company’s Insider Trading Policy,

including all restrictions on trading in Company’s securities while in possession of material non-public information. This obligation

shall survive termination of this Agreement.

16.

Indemnification; Advancement; and D&O Coverage

the fullest extent permitted by applicable law and Company’s charter, bylaws, or similar governing documents, Company shall indemnify,

defend, and hold harmless Consultant from and against any and all claims, losses, damages, liabilities, judgments, penalties, costs,

and expenses (including reasonable attorneys’ fees and expenses) arising out of or relating to acts or omissions taken by Consultant

in good faith in the course of performing the Services, provided that Consultant acted in a manner Consultant reasonably believed to

be in, or not opposed to, the best interests of Company, and excluding any matters arising from Consultant’s gross negligence,

willful misconduct, fraud, or material breach of this Agreement. Company shall advance reasonable legal fees and expenses incurred by

Consultant in connection with any covered matter, subject to repayment only to the extent a final non-appealable determination establishes

that Consultant is not entitled to indemnification under this Section.

Consultant is appointed or deemed by Company to serve in an officer-like, interim executive, or similar senior financial leadership capacity

for any purpose, Company shall provide Consultant indemnification rights and advancement rights on terms no less favorable in all material

respects than those provided to Company’s other senior executive officers serving in comparable capacities, subject to the exclusions

stated above. Company shall, at its expense, obtain and maintain directors’ and officers’ liability insurance, including

Side A coverage to the extent maintained for similarly situated executive officers, that includes Consultant as an insured person (or

its functional equivalent) during the period Consultant is providing Services in such capacity, if any, and for any applicable tail or

extended reporting period coverage maintained for Company’s similarly situated executive officers after Consultant ceases providing

Services in such capacity. Nothing in this Agreement shall require Company to provide broader coverage than that maintained for its similarly

situated executive officers or to cover acts outside the scope of the Services.

Consultant

shall indemnify, defend, and hold harmless Company from and against any claims, losses, damages, liabilities, judgments, penalties, costs,

and expenses (including reasonable attorneys’ fees) arising out of or relating to Consultant’s gross negligence, willful

misconduct, fraud, or material breach of this Agreement or violation of applicable law. The obligations in this Section shall survive

termination or expiration of this Agreement.

17.

Limitation of Liability

Except

for liability arising from a Party’s fraud, willful misconduct, gross negligence, breach of confidentiality, infringement or misappropriation

of intellectual property, or indemnification obligations under this Agreement, neither Party shall be liable to the other for any consequential,

incidental, special, exemplary, punitive, or indirect damages, including lost profits, diminution in value, or lost opportunity, whether

in contract, tort, or otherwise, even if advised of the possibility of such damages.

Except

for liabilities excluded from the foregoing sentence and except for amounts owed for Services rendered, Consultant’s aggregate

liability arising out of or relating to this Agreement shall not exceed the total cash compensation actually paid to Consultant under

this Agreement during the twelve (12) months immediately preceding the event giving rise to the claim. The Parties acknowledge that the

foregoing allocation of risk is a material basis of the bargain reflected in this Agreement.

18.

Non-Disparagement

Consultant

agrees not to make, publish, or communicate any maliciously false, defamatory, or disparaging statements about Company, its affiliates,

or their officers, directors, employees, contractors, business partners, or investors, whether publicly or privately. Likewise, Company

agrees that its directors and senior executives will not make, publish, or communicate any maliciously false, defamatory, or disparaging

statements regarding Consultant. Nothing in this Agreement restricts either Party from making truthful statements required by law or

from communicating with regulators or government agencies.

19.

Social Media and Public Statements

Consultant

agrees not to make any public statements, posts, or endorsements about or relating to Company, its securities, or its business on social

media, in press releases, or in interviews, without prior written approval of Company’s Chief Executive Officer or other authorized

designee. Consultant shall not represent Consultant as a Company spokesperson unless expressly authorized in writing.

20.

Non-Competition and Non-Solicitation

During

the Term of this Agreement and for a period of one (1) year thereafter, Consultant shall not directly solicit for employment any employee

of Company with whom Consultant had material contact in connection with the Services, nor solicit for competing services any customer,

investor, lender, or referral source of Company with whom Consultant had direct substantive contact through the Services, in each case

using Company Confidential Information. Nothing herein shall prohibit general solicitations not specifically targeted at such persons

or providing services to other clients so long as Consultant complies with the confidentiality and information-barrier obligations of

this Agreement.

21.

Dispute Resolution

The

Parties agree to attempt to resolve any dispute arising out of or relating to this Agreement through good-faith discussions. If the dispute

cannot be resolved informally within thirty (30) days, then the Parties agree to submit the matter to binding arbitration in the State

of Florida, in accordance with the rules of the American Arbitration Association (“AAA”), unless the Parties mutually agree

otherwise in writing. The arbitrator may award legal and equitable relief consistent with this Agreement and applicable law.

22.

Miscellaneous

Entire Agreement.

This

Agreement constitutes the full understanding between the Parties and supersedes all prior agreements, discussions, or understandings,

whether oral or written, relating to the subject matter hereof. No amendment shall be valid unless in writing and signed by both Parties.

Notices.

All

notices must be in writing and delivered personally, by nationally recognized courier, or by email with confirmation of transmission

to the addresses listed above or to such other address as either Party may designate by notice.

Governing Law.

This

Agreement shall be governed by and construed in accordance with the laws of the State of Florida, without regard to conflicts-of-laws

principles.

Severability.

any provision of this Agreement is held invalid or unenforceable, the remaining provisions shall continue in full force and effect and

shall be construed to give effect as nearly as possible to the original intent of the Parties.

Survival.

The

rights and obligations of the Parties that by their nature extend beyond termination or expiration of this Agreement shall survive, including

without limitation Sections 3, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 22.

Counterparts and Electronic Signatures.

This

Agreement may be executed in counterparts and delivered electronically. A copy transmitted by email or electronic signature platform

shall be deemed an original and enforceable.

WITNESS WHEREOF, the Parties have executed this Consulting Agreement as of the Effective Date.

MIRA

Pharmaceuticals, Inc.:

CONSULTANT:

By:

/s/

Erez Aminov

By:

/s/

Andriy Mushak

Name:

Erez

Aminov

Name:

Andriy

Mushak

Title:

Chairman

and Chief Executive Officer

Title

Fractional

CFO

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 02, 2026

Entity File Number

001-41765

Entity Registrant Name

MIRA

PHARMACEUTICALS, INC.

Entity Central Index Key

0001904286

Entity Tax Identification Number

85-3354547

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1200

Brickell Avenue

Entity Address, Address Line Two

Suite 1950 #1183

Entity Address, City or Town

Miami

Entity Address, State or Province

Entity Address, Postal Zip Code

33131

City Area Code

(786)

Local Phone Number

432-9792

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value per share

Trading Symbol

MIRA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration